ArticleNeuropsychiatric disease and treatment2006
Zonisamide - a review of experience and use in partial seizures.
Article in Neuropsychiatric disease and treatment, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Applications of Carbonic Anhydrase Inhibitors in Neurological Disorders, Mechanisms and Therapeutic Potential.Sub-cellular biochemistry · 2026Review
- Small Molecule NS11021 Promotes BK Channel Activation by Increasing Inner Pore Hydration.Journal of chemical information and modeling · 2024Article
- Challenges in the Therapeutic Targeting of KCa Channels: From Basic Physiology to Clinical Applications.International journal of molecular sciences · 2024Review
- Zonisamide: A Comprehensive, Updated Review for the Clinician.Neurology. Clinical practice · 2024Review
- iGRLDTI: an improved graph representation learning method for predicting drug-target interactions over heterogeneous biological information network.Bioinformatics (Oxford, England) · 2023Article
- Zonisamide-induced distal renal tubular acidosis and critical hypokalaemia.BMJ case reports · 2023Article
- Bioequivalence of Different Formulations of Zonisamide Oral Suspensions: A Short Review.Patient preference and adherence · 2023Review
- Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives.Molecules (Basel, Switzerland) · 2021Review
- Zonisamide in Parkinson's disease: a current update.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Review
- TRPC1/5-CaFrontiers in neuroscience · 2021Article
- Genetic Deletion of KLHL1 Leads to Hyperexcitability in Hypothalamic POMC Neurons and Lack of Electrical Responses to Leptin.Frontiers in neuroscience · 2021Article
- A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures.Inflammopharmacology · 2018Article
- Evaluation of safety and efficacy of zonisamide in adult patients with partial, generalized, and combined seizures: an open labeled, noncomparative, observational Indian study.Therapeutics and clinical risk management · 2016Article
- Protective effect of melatonin against zonisamide-induced reproductive disorders in male rats.Archives of medical science : AMS · 2015Article
- Newer antiepileptic drugs: evidence based use.Indian journal of pediatrics · 2014Review
- Newer anticonvulsant medications in pediatric neurology.Current treatment options in neurology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zonisamide is a modern antiepileptic drug (AED) that is distinguished from other AEDs by its unique structure and broad mechanistic profile. Preclinical studies have reported a range of potential mechanisms of action for zonisamide, such as blocking voltage-gated sodium channels, reduction of T-type calcium channel currents, and enhancement of gamma-aminobutyric acid (GABA)-mediated inhibition, which are indicative of its broad antiseizure effects. Zonisamide has a favorable linear pharmacokinetic profile, a long half-life, and a low incidence of protein-binding interactions with other AEDs. Hepatically metabolized through the cytochrome P450 pathway, zonisamide does not induce its own metabolism or liver enzymes. For more than 2 decades, zonisamide has been extensively used as monotherapy and adjunctive therapy for the treatment of partial and generalized seizures in pediatric and adult patients in Japan. Zonisamide was approved in the USA in 2000 as adjunctive therapy for partial seizures in adults. With over 2 million patient-years of exposure internationally, zonisamide has demonstrated safety and efficacy against a multitude of epilepsy and seizure types, including both partial and generalized seizures. This review focuses on the experience and use of zonisamide in partial seizures, as well as possible new uses for zonisamide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.